Suggested remit: To appraise the clinical and cost effectiveness of upadacitinib within its marketing authorisation for treating giant cell arteritis.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6299
Provisional Schedule
- Committee meeting:
- 14 October 2025
- Expected publication:
- 25 February 2026
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Warwick Evidence, Warwick Medical School, University of Warwick
Stakeholders
- Companies sponsors
- AbbVie
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- PMRGCA UK (Polymyalgia Rheumatica & Giant Cell Arteritis UK)
- Vasculitis UK
- Professional groups
- British Society for Rheumatology
- Royal College of Physicians
- Associated public health groups
- None
- Comparator companies
- Fresenius Kabi (tocilizumab) – confidentiality agreement not signed, not participating
- Roche (tocilizumab) – confidentiality agreement signed, participating
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health – Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- None
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 May 2025 | The final stakeholder list was updated in May 2025 to include a relevant provisional consultee. |
| 14 March 2025 | Invitation to participate |
| 23 January 2025 - 20 February 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6299 |
| 23 January 2025 | In progress. Scoping commencing |
| 06 December 2024 | Please note that following on from a request received from the company, this appraisal has been scheduled back into the work programme. The appraisal is now anticipated to begin in mid-March 2025 when we will write to you about how you can get involved. |
| 13 May 2024 | Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. |
| 28 April 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual